L. Nicolas Gonzalez Castro, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 12 | 2024 | 9025 | 1.100 |
Why?
|
Glioma | 6 | 2023 | 3452 | 0.840 |
Why?
|
Stuttering | 1 | 2018 | 25 | 0.630 |
Why?
|
Neurotoxicity Syndromes | 2 | 2019 | 301 | 0.600 |
Why?
|
Adaptation, Physiological | 3 | 2014 | 1301 | 0.570 |
Why?
|
Carotid-Cavernous Sinus Fistula | 1 | 2016 | 37 | 0.520 |
Why?
|
Hospitals, Military | 1 | 2016 | 62 | 0.510 |
Why?
|
Antigens, CD19 | 1 | 2018 | 424 | 0.510 |
Why?
|
Midazolam | 1 | 2017 | 267 | 0.490 |
Why?
|
Tumor Microenvironment | 7 | 2024 | 3875 | 0.480 |
Why?
|
Tidal Volume | 1 | 2017 | 488 | 0.470 |
Why?
|
Military Medicine | 1 | 2016 | 184 | 0.450 |
Why?
|
Neurology | 1 | 2021 | 784 | 0.440 |
Why?
|
Central Nervous System Neoplasms | 1 | 2021 | 915 | 0.420 |
Why?
|
Single-Cell Analysis | 5 | 2024 | 2452 | 0.420 |
Why?
|
Fellowships and Scholarships | 1 | 2021 | 1115 | 0.420 |
Why?
|
Brain Diseases | 2 | 2018 | 1545 | 0.400 |
Why?
|
Immunotherapy, Adoptive | 2 | 2019 | 1468 | 0.400 |
Why?
|
Isocitrate Dehydrogenase | 5 | 2024 | 937 | 0.370 |
Why?
|
Arm | 2 | 2011 | 589 | 0.370 |
Why?
|
Learning | 4 | 2014 | 1737 | 0.360 |
Why?
|
Glioblastoma | 5 | 2024 | 3482 | 0.350 |
Why?
|
Medical Oncology | 1 | 2021 | 2320 | 0.340 |
Why?
|
Psychomotor Performance | 2 | 2014 | 1880 | 0.320 |
Why?
|
Vision Disorders | 1 | 2016 | 1089 | 0.320 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 1869 | 0.320 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 1405 | 0.310 |
Why?
|
T-Lymphocytes | 4 | 2023 | 10203 | 0.310 |
Why?
|
Respiratory Insufficiency | 1 | 2017 | 1232 | 0.300 |
Why?
|
Environment | 1 | 2014 | 1122 | 0.300 |
Why?
|
Movement | 2 | 2014 | 1476 | 0.290 |
Why?
|
Genomics | 1 | 2023 | 5829 | 0.280 |
Why?
|
Seizures | 1 | 2020 | 2965 | 0.270 |
Why?
|
Military Personnel | 1 | 2016 | 1246 | 0.270 |
Why?
|
Epilepsy | 1 | 2022 | 3304 | 0.270 |
Why?
|
Anesthesia | 1 | 2017 | 1591 | 0.250 |
Why?
|
Neoplasms | 3 | 2023 | 22142 | 0.220 |
Why?
|
Models, Neurological | 1 | 2011 | 1769 | 0.210 |
Why?
|
Wounds and Injuries | 1 | 2016 | 2493 | 0.210 |
Why?
|
Oligodendroglioma | 1 | 2024 | 278 | 0.200 |
Why?
|
Genetic Heterogeneity | 2 | 2023 | 734 | 0.200 |
Why?
|
Motor Activity | 1 | 2011 | 2712 | 0.190 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2021 | 84 | 0.180 |
Why?
|
Oncolytic Viruses | 1 | 2023 | 344 | 0.170 |
Why?
|
Inheritance Patterns | 1 | 2021 | 341 | 0.160 |
Why?
|
Computational Biology | 1 | 2011 | 3499 | 0.160 |
Why?
|
Herpesvirus 1, Human | 1 | 2023 | 739 | 0.150 |
Why?
|
Oncolytic Virotherapy | 1 | 2023 | 515 | 0.150 |
Why?
|
Artificial Intelligence | 1 | 2011 | 2576 | 0.140 |
Why?
|
World War I | 1 | 2016 | 14 | 0.130 |
Why?
|
Lung Volume Measurements | 1 | 2017 | 375 | 0.130 |
Why?
|
Respiratory Rate | 1 | 2017 | 176 | 0.130 |
Why?
|
Humans | 26 | 2024 | 761222 | 0.130 |
Why?
|
World Health Organization | 1 | 2021 | 1321 | 0.120 |
Why?
|
Central Nervous System | 1 | 2021 | 1333 | 0.110 |
Why?
|
Administration, Oral | 1 | 2022 | 4015 | 0.110 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2024 | 8531 | 0.100 |
Why?
|
Individuality | 1 | 2014 | 303 | 0.100 |
Why?
|
Anticonvulsants | 1 | 2022 | 1910 | 0.100 |
Why?
|
Mutation | 4 | 2024 | 30004 | 0.090 |
Why?
|
Cerebral Angiography | 1 | 2016 | 1281 | 0.090 |
Why?
|
Prognosis | 2 | 2021 | 29688 | 0.080 |
Why?
|
Biological Products | 1 | 2018 | 915 | 0.080 |
Why?
|
Monitoring, Physiologic | 1 | 2017 | 1780 | 0.080 |
Why?
|
Europe | 1 | 2016 | 3423 | 0.080 |
Why?
|
Hand Strength | 1 | 2011 | 456 | 0.080 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 3788 | 0.070 |
Why?
|
Adult | 8 | 2023 | 221120 | 0.070 |
Why?
|
History, 20th Century | 1 | 2016 | 2765 | 0.070 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7571 | 0.070 |
Why?
|
Task Performance and Analysis | 1 | 2011 | 763 | 0.070 |
Why?
|
Clinical Trials as Topic | 1 | 2023 | 8002 | 0.070 |
Why?
|
Reward | 1 | 2014 | 968 | 0.070 |
Why?
|
Cell Differentiation | 1 | 2024 | 11512 | 0.070 |
Why?
|
Embolization, Therapeutic | 1 | 2016 | 1419 | 0.070 |
Why?
|
Anticoagulants | 1 | 2022 | 4795 | 0.070 |
Why?
|
Child | 3 | 2023 | 80154 | 0.060 |
Why?
|
Bayes Theorem | 1 | 2011 | 2329 | 0.050 |
Why?
|
Cell Lineage | 2 | 2024 | 2549 | 0.050 |
Why?
|
Boston | 1 | 2016 | 9327 | 0.050 |
Why?
|
Female | 9 | 2019 | 392552 | 0.050 |
Why?
|
Oncostatin M Receptor beta Subunit | 1 | 2021 | 4 | 0.050 |
Why?
|
Leukemia Inhibitory Factor Receptor alpha Subunit | 1 | 2021 | 30 | 0.050 |
Why?
|
Cytokine Receptor gp130 | 1 | 2021 | 66 | 0.050 |
Why?
|
Oncostatin M | 1 | 2021 | 42 | 0.050 |
Why?
|
Aged, 80 and over | 2 | 2017 | 58952 | 0.050 |
Why?
|
Receptor, Notch1 | 1 | 2024 | 497 | 0.050 |
Why?
|
Adolescent | 4 | 2019 | 88300 | 0.040 |
Why?
|
Tumor Escape | 1 | 2021 | 371 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2021 | 585 | 0.040 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2021 | 1351 | 0.040 |
Why?
|
Treatment Outcome | 3 | 2023 | 64681 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 7407 | 0.040 |
Why?
|
CpG Islands | 1 | 2021 | 1190 | 0.030 |
Why?
|
STAT3 Transcription Factor | 1 | 2021 | 872 | 0.030 |
Why?
|
Male | 7 | 2019 | 360703 | 0.030 |
Why?
|
Astrocytes | 1 | 2024 | 1341 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1089 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2019 | 1822 | 0.030 |
Why?
|
Cephalosporins | 1 | 2016 | 198 | 0.030 |
Why?
|
Metronidazole | 1 | 2016 | 232 | 0.030 |
Why?
|
Mice | 4 | 2024 | 81330 | 0.030 |
Why?
|
Young Adult | 3 | 2019 | 59222 | 0.030 |
Why?
|
Phylogeny | 1 | 2021 | 2809 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2021 | 16954 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3134 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2021 | 1985 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2021 | 1803 | 0.030 |
Why?
|
Penicillins | 1 | 2016 | 403 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2021 | 2024 | 0.030 |
Why?
|
Middle Aged | 5 | 2019 | 220858 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2021 | 22128 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2021 | 2194 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 2021 | 2802 | 0.020 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2019 | 1372 | 0.020 |
Why?
|
Nonlinear Dynamics | 1 | 2014 | 492 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2023 | 3671 | 0.020 |
Why?
|
Survival Analysis | 1 | 2023 | 10088 | 0.020 |
Why?
|
Aged | 3 | 2019 | 169292 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2021 | 18222 | 0.020 |
Why?
|
Algorithms | 1 | 2011 | 14025 | 0.020 |
Why?
|
Proteomics | 1 | 2024 | 3840 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2021 | 5773 | 0.020 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1549 | 0.020 |
Why?
|
Animals | 4 | 2024 | 168089 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2021 | 9520 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2024 | 10423 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2507 | 0.020 |
Why?
|
Immunotherapy | 1 | 2023 | 4642 | 0.020 |
Why?
|
DNA Methylation | 1 | 2021 | 4384 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2293 | 0.020 |
Why?
|
Cohort Studies | 2 | 2019 | 41496 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2021 | 18927 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2023 | 20118 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9417 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4310 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 15308 | 0.010 |
Why?
|
Infant | 1 | 2019 | 36170 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2023 | 36415 | 0.010 |
Why?
|
Time Factors | 1 | 2014 | 39957 | 0.010 |
Why?
|